Titre : Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6
link : Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6
Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6
Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]
Grebely J1, Dore GJ2, Alami NN3, Conway B4, Dillon JF5, Gschwantler M6, Felizarta F7, Hézode C8, Tomasiewicz K9, Fredrick LM3, Dumas EO3, Mensa FJ3.
Open Access
BACKGROUND:
International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and pibrentasvir has shown high sustained virologic response at post-treatment Week 12 (SVR12) in clinical trials. Herein, we evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients receiving OST.
Pooled data from patients with HCV genotypes 1-6 who were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight Phase 2 and 3 trials were categorized by use of OST. Treatment completion, treatment adherence, SVR12, adverse events (AEs), and laboratory abnormalities were evaluated for patients receiving and not receiving OST.
Among 2256 patients, 157 (7%) were receiving OST. Compared with patients not receiving OST, OST patients were younger (mean age, 46.8 vs 52.8 years), male (69% vs 54%), white (93% vs 80%), HCV treatment-naïve (86% vs 72%), had HCV genotype 3 (60% vs 26%), and had a history of depression or bipolar disorder (43% vs 19%). Most patients completed (OST: 98% [n/N = 154/157]; non-OST: 99% [n/N = 2070/2099]) and were adherent (received ≥90% of study drug doses) to glecaprevir/pibrentasvir treatment (OST: 98% [n/N = 121/123]; non-OST: 99% [n/N = 1884/1905] among patients with available data). In the intention-to-treat population, SVR12 rates in OST and non-OST patients were 96.2% (n/N = 151/157; 95% CI 93.2-99.2) and 97.9% (n/N = 2055/2099; 95% CI 97.3-98.5), respectively. For OST patients, reasons for nonresponse included virologic relapse (<1%; n = 1), premature study drug discontinuation (<1%; n = 1), and loss to follow-up (3%; n = 4). AEs occurring in ≥10% of OST patients were headache, fatigue, and nausea. Drug-related serious AEs, AEs leading to study drug discontinuation, and Grade 3 or higher laboratory abnormalities were infrequent in both groups (<1%). No HCV reinfections occurred through post-treatment Week 12.
Glecaprevir/pibrentasvir is highly efficacious and well tolerated in HCV-infected patients receiving OST.
Full-text article available online: https://www.sciencedirect.com/science/article/pii/S0955395919300192?via%3Dihub
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
KEYWORDS: Glecaprevir/pibrentasvir; Hepatitis C virus; Opioid substitution therapy; People who inject drugs
Thus articles Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6
that is all articles Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6 This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6 the link address https://newsaninpiration.blogspot.com/2019/02/mavyret-safety-and-efficacy-in-patients.html
0 Response to "Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6"
Post a Comment